Overview
- Viking released top‑line maintenance results on Tuesday showing VK2735 produced a 22% placebo‑adjusted weight loss over 33 weeks at the 17.5 mg weekly dose.
- In the 21‑week induction phase, once‑weekly VK2735 delivered about 16% to 19% mean weight loss versus roughly 0% for placebo.
- During the 12‑week maintenance phase, every‑other‑week dosing preserved up to 97% of prior weight loss and monthly dosing preserved up to 90%, while the placebo group retained 61%.
- Maintenance safety was favorable, with gastrointestinal adverse event rates similar to placebo and only a small number of discontinuations reported.
- The readout sent Viking shares sharply higher and divided analysts; the company reported about $502 million in cash and plans a Part 2 to test oral maintenance dosing as the market watches for longer, larger trials and head‑to‑head data.